
In the Amazon basin, knowledge of plants has developed through generations of observation, practice and cultural exchange. Among the best-known examples is ayahuasca, a traditional psychoactive preparation associated with Indigenous and other communities across parts of South America. It has attracted international attention as a subject of neuroscience and mental-health research, but its story cannot be reduced to a promising molecule or a fashionable retreat experience.
A partnership between plants
Ayahuasca is commonly associated with a combination of the woody vine Banisteriopsis caapi and leaves from a DMT-containing plant, often Psychotria viridis. The precise botanical composition and terminology vary across regions and traditions. The chemistry is unusual because DMT is not normally orally active in the same way when taken alone: compounds in the vine, including harmine and harmaline, inhibit monoamine oxidase-A, an enzyme involved in breaking down certain neurotransmitters and DMT.
This interaction helps explain the preparation’s distinctive pharmacology. It is an example of how plant combinations can produce effects that are not obvious from studying each ingredient in isolation. It is not, however, a safe or predictable formula: botanical variation, individual health, other medicines and preparation differences can all matter.
Tradition, ceremony and cultural context
Ayahuasca has diverse roles in Amazonian Indigenous societies, including healing, spiritual practice, social life and forms of knowledge-making. In more recent history it has also become important in syncretic religious movements and international ceremonial settings. These practices are not interchangeable. The beliefs, responsibilities and safeguards of a local tradition cannot simply be assumed to travel with a commercial service operating elsewhere.
The rapid growth of international interest has raised questions about cultural appropriation, benefit-sharing, intellectual property and the distribution of economic gains. Communities that have maintained knowledge of these plants may receive little of the financial benefit generated by global demand.
What happens in the brain?
DMT acts on several serotonin receptors, including the 5-HT2A receptor, which is strongly associated with the effects of classic psychedelics. Harmala alkaloids have additional pharmacological actions, making ayahuasca a more complex mixture than a single-compound drug. Researchers are investigating how these effects relate to perception, emotion, memory and brain networks.
A growing body of research has examined possible effects on depression, anxiety, substance-use problems and psychological wellbeing. A 2026 review surveys studies of ayahuasca, DMT and mental health, while earlier reviews describe promising but still limited findings. Much of the evidence comes from small studies, observational research or carefully controlled settings. Results cannot automatically be generalised to unsupervised use or to people with different medical histories.
The risks are real
Ayahuasca can produce intense psychological and physical effects, including nausea, vomiting, changes in blood pressure and heart rate, anxiety, confusion and distressing experiences. The interaction between harmala alkaloids and other substances is particularly important: monoamine oxidase inhibition can create potentially serious interactions with some prescription medicines and other drugs.
A 2024 systematic review of adverse events and toxicity discusses a range of reported harms and clinical considerations. People with certain cardiovascular or psychiatric vulnerabilities may face additional risks. The existence of clinical research does not make a traditional or commercial ceremony equivalent to a regulated medical treatment, and it does not establish that ayahuasca is safe for everyone.
A rainforest conservation question
The ayahuasca vine is cultivated in some regions, but increasing demand can still raise questions about sourcing, land use and the sustainability of associated plants. A 2025 conservation review identifies ayahuasca among psychedelic species for which ecological data and long-term monitoring remain incomplete. It argues for conservation approaches that recognise both biodiversity and the rights and knowledge of local communities.
The ecological impact cannot be assessed by looking at the vine alone. Harvesting practices, cultivation systems, supply chains, habitat change and the demand for other botanical ingredients all influence the wider picture. Sustainable sourcing requires evidence rather than assumptions that a plant-based product is automatically environmentally benign.
Medicine, knowledge and responsibility
Ayahuasca sits at the meeting point of traditional knowledge, modern pharmacology and a fast-changing global market. Scientific research may help identify mechanisms and test possible therapeutic applications, but it must be conducted with rigorous safeguards and respect for the people whose knowledge has helped keep these traditions alive.
The most useful question is not whether ayahuasca is a miracle cure or merely a dangerous intoxicant. It is what careful research can establish, for whom any potential benefits might apply, what harms must be prevented, and how cultural and ecological responsibilities can be honoured as interest grows.
Sources and further reading
- Ayahuasca: pharmacology, safety and therapeutic effects (2025)
- Araújo et al. (2026), Ayahuasca, DMT and mental health: a current review
- White et al. (2024), adverse events and toxicity analysis
- Ermakova and Gandy (2025), psychedelic species of conservation concern
- Creative Commons Attribution-ShareAlike 4.0 licence
